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Table 3
Associations Between Risk Factors and Cogstate Composite Scores
DET + IDN (n¼l,580)
(psychomotor speed, attention)
OCL + ONB (n¼l,505) (learning,
working memory) Overall Cognition (n¼l,469)
b p b p b p
Age (years) -0.03 (-0.04, -0.02) <0.001 -0.04 (-0.04, -0.03) <0.001 -0.03 (-0.04, -0.03) <0.001
Smoking
Never (ref.) - - - - - -
Former/Current -0.04 (-0.13,0.06) 0.47 0.10(0.02,0.18) 0.02 0.04 (-0.03,0.12) 0.26
Body mass index
<22 kg/m2 -0.01 (-0.18,0.16) 0.88 -0.08 (-0.23,0.06) 0.27 -0.04 (-0.17,0.09) 0.57
22-24.9 kg/m2 (ref.) - - - - - -
25-29.9 kg/m2 0.02 (-0.09,0.12) 0.74 0.00 (-0.09,0.09) 0.94 0.01 (-0.07,0.09) 0.82
30+ kg/m2 0.10 (-0.05,0.25) 0.18 0.03 (-0.10,0.16) 0.61 0.06 (-0.06,0.17) 0.34
Physical activity, MET-hr/wk
First quartile (ref.) - - - - - -
Second quartile 0.04 (-0.04,0.17) 0.50 0.03 (-0.08,0.14) 0.57 0.01 (-0.09,0.11) 0.83
Third quartile 0.01 (-0.12,0.14) 0.86 0.00 (-0.11,0.11) 0.99 -0.02 (-0.12,0.08) 0.70
Fourth quartile 0.08 (-0.05,0.21) 0.25 0.01 (-0.11,0.12) 0.89 0.00 (-0.10,0.11) 0.95
Alcohol, drinks/day
None (ref.) - - - - - -
1-2 0.09 (-0.01,0.19) 0.06 0.03 (-0.05,0.11) 0.45 0.05 (-0.03,0.12) 0.21
>2 -0.03 (-0.16,0.11) 0.67 -0.02 (-0.13,0.10) 0.77 -0.03 (-0.13,0.07) 0.56
Nut intake, times/day
First quartile (ref.) - - - - - -
Second quartile 0.10 (-0.02,0.23) 0.10 0.11 (0.01,0.22) 0.04 0.11 (0.02,0.21) 0.02
Third quartile 0.15 (0.01,0.28) 0.03 0.16 (0.05,0.25) 0.005 0.18 (0.07,0.28) 0.001
Fourth quartile 0.08 (-0.06,0.21) 0.26 0.07 (-0.04,0.19) 0.21 0.09 (-0.01,0.20) 0.09
Diabetes -0.18 (-0.34, -0.02) 0.03 0.09 (-0.04,0.23) 0.18 -0.05 (-0.18, 0.07) 0.42
Hypertension -0.07 (-0.16,0.02) 0.12 -0.08 (-0.16,-0.01) 0.03 -0.08 (-0.15, -0.01) 0.03
Myocardial infarction 0.10 (-0.08,0.27) 0.26 0.02 (-0.13,0.16) 0.80 0.05 (-0.09,0.18) 0.48
Notes: Higher scores indicate better performance. All variables were placed into the same model
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was significantly associated with worse performance on overall
cognition (mean difference¼-0.08 standard units [95% CI
-0.15, -0.01]) and higher nut consumption was also significantly
associated with better performance (Q3 vs. Q1: 0.11 [0.02, 0.21];
Q2 vs. Q1: 0.18 [0.07, 0.28]). When using covariates measured at
mid-life, increased physical activity was also significantly asso-
ciated with better performance on learning and working memory
(Q3 vs. Q1: 0.14 [0.04, 0.24]). Conclusions:Participation in self-
administered computerized cognitive testing in older men was
low. However, few differences existed between responders and
non-responders. The battery showed significant associations
with several risk factors known to be associated with cognitive
function. Future epidemiologic studies of cognitive aging may
benefit from the numerous advantages of self-administered
computerized testing.
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Background: Alzheimer’s disease (AD) is a common heritable
neurodegenerative disorder. However, aside from ApoEe4, the
genetic factors contributing to common late-onset AD remain
to be elucidated. In addition to known single genetic risk factor
(ApoEe4 allele) and highly penetrant missense-mutations in
APP and PSEN1/PSEN2 genes, many other genetic variations
with incomplete penetrance may potentially be risk factors
for AD. The role of such rare variations in AD would be diffi-
cult or impossible to identify by GWAS using a standard pop-
ulation case-control design. Thus, we employed the direct
whole-genome sequencing of AD patients from a genetically
isolated population from the southwestern area of The
Netherlands. Methods: We have performed a whole-genome
sequencing of pairs of distantly-related late-onset AD patients
from extra-large pedigree branches from genetically isolated
Dutch population, described previously (Liu et al, Am J Hum
Genet,2007). The genome sequencing data were combined
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these pedigrees, which identified a set of AD susceptibility chro-
mosomal loci, including 1q25, 1q21, 11q24 and 3q23 loci. Re-
sults:We selected rare single nucleotide variations (SNV) and
insertion deletion (indel) mutations shared between at least
two AD patients in each pedigree branch. We searched only
for the rare variations with MAF<0.05 that potentially affect
protein structure. We filtered out potential sequencing errors
and also removed the SNV/indels found in “controls,” including
genomes of centenarians with no AD symptoms (Illumina
sequencing data). The deleterious effects were verified by
computational programs. In the primary analysis, we selected
the genes with SNVs/indels located on 1q25, 1q21, 11q24
and 3q23 loci. In a broader whole-genome scanning, we listed
all the rare variations that had an effect on protein structure and
which are shared between at least two affected, distantly-
related individuals. Conclusions: The data suggested that not a
single, but many genetic variations may be involved in risk and
modulation of AD pathway, even in a genetic isolate with com-
mon genetic founders. A set of candidate genes bearing rare var-
iations in AD patients which are involved in Abeta/tau–
metabolism and regulation and in neurodegeneration-related
biological processes were revealed and their role will be dis-
cussed.
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Background:Mutations in APP, PSEN1 and PSEN2 lead to early-
onset Alzheimer disease (EOAD). These mutations account for
w11% of EOAD overall, leaving the majority of genetic risk
for the most severe form of Alzheimer disease unexplained.
Methods: We performed Whole-Exome Sequencing (WES) in
50 Caucasian EOAD cases previously screened negative for
APP, PSEN1, and PSEN2 to search for rare variants contributing
to risk for EOAD. Variant filtering for functional, damaging
rare variants (MAF<0.1%) was performed. Genes with shared
(2+ cases with the same variant), damaging variants were exam-
ined for interactions with known EOAD genes (APP, PSEN1,
PSEN2, SORL1, GRN, MAPT) and APOE using STRINGdb. Re-
sults: 176 genes had rare functional variants shared in two or
more cases. 46 of these genes were prioritized for their
damaging potential, defined by their shared rare variants having
a Combined Annotation Dependent Depletion (CADD) score in
the top 10% of all variants. Gene network analysis of these 46
genes with known EOAD genes and APOE identified five top
candidate genes: HSPG2 (interacts with GRN, APOE, and
APP), CLSTN1 (interacts with PSEN1 and APP), DOCK3 (inter-
acts with PSEN1 and PSEN2), and the APOE interactors SAR1B
and STAT1. 5 cases have a variant in HSPG2, a gene potentially
involved in amyloidogenesis and tau aggregation in AD, while 4
cases have a variant in DOCK3, a gene expressed exclusively in
the central nervous system and associated with neurofibrillarytangles in AD brains. Conclusions:WES of EOAD cases identi-
fied several genes with potential roles in AD pathogenesis.
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Background:Due to the increasing number of genes associated
with neurodegenerative brain diseases (NBDs) like Alzheimer
disease (AD), frontotemporal lobar degeneration (FTLD) and
related neurodegenerative diseases, and taken the significant
overlap in clinical phenotype between these diseases, there is
a growing need for high-throughput genetic profiling assays.
Methods:We designed a diagnostic gene panel for amplicon-based
re-sequencing of all coding exons of 14 Mendelian genes linked to
NBDs. The assay uses high-level multiplex PCR amplification fol-
lowed by sequencing on an Illumina MiSeq. Results: In 527 FTLD
patients from Belgium, we identified 146 rare protein-modifying
variants. These included 55 variants that were definitely or prob-
ably pathogenic (38GRN LOF, 4MAPT, 7VCP, 1FUS, 2TARDBP,
1CHMP2B, 2PSEN1) and 5 possibly pathogenic (2VCP, 2FUS,
1PSEN1). Together with the C9orf72 repeat expansions, these mu-
tations explained 43% of familial FTLD patients and up to 62% of
pathology confirmed patients in our cohort. In one probable FTLD
patient of 55 years, we observed a C9orf72 repeat expansion
together with a novel VCP p.Ile189Val mutation. Other interesting
observations were a.o. the presence of 8 novel APP non-synony-
mous mutations of which the pathological nature is uncertain.
Nonetheless, we identified the APP p.Glu599Lys mutation in 2
probable FTLD patients and one patient diagnosed with probable
AD or probable DLB, and all 3 patients shared a common haplo-
type. In addition, in MAPT non-synonymous mutations outside
exon 1 and exon 9-13 were found in multiple FTLD patients,
Val244Gly (N¼4) and Ser427Phe (N¼ 5). These findings are inter-
esting since they cross borders between different clinical diagnostic
disease categories. However, further studies are needed to see
whether these genetic variations contribute to the clinical and/or
neuropathological presentations of the carriers or might have dis-
ease modifying effects. Conclusions:The NBD gene panel is a high
throughput and cost effective molecular diagnostic tool that offers a
more completegenetic readout than classic Sanger sequencing-based
gene by gene testing. Moreover it allows the systematic evaluation of
the prevalence and relevance of double and cross-phenotype muta-
tions. At this moment, exome sequencing cannot yet offer the same
amount of coverage and fidelity for targeted gene screening.
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